Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bioxcel Therapeutics Inc.

1.82
+0.185011.35%
Volume:796.29K
Turnover:1.41M
Market Cap:39.69M
PE:-0.15
High:1.86
Open:1.64
Low:1.63
Close:1.63
52wk High:9.78
52wk Low:1.17
Shares:21.87M
Float Shares:19.10M
Volume Ratio:1.01
T/O Rate:4.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.2842
EPS(LYR):-23.5105
ROE:-1766.94%
ROA:-67.31%
PB:-0.45
PE(LYR):-0.08

Loading ...

Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI) and Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Nov 13

BioXcel Therapeutics Q3 revenue misses analyst expectations

Reuters
·
Nov 12

BRIEF-BioXcel Therapeutics Q3 Basic EPS USD -2.18 Vs. IBES Estimate USD -1.24

Reuters
·
Nov 12

BioXcel Therapeutics Q3 Basic EPS USD -2.18 VS. Ibes Estimate USD -1.24

THOMSON REUTERS
·
Nov 12

BioXcel Therapeutics Q3 Revenue USD 98 Thousand VS. Ibes Estimate USD 216 Thousand

THOMSON REUTERS
·
Nov 12

BioXcel Therapeutics Reports Phase 3 Study Results on BXCL501 for Agitation in Bipolar Disorder and Schizophrenia at Home

Reuters
·
Nov 10

BioXcel Therapeutics Inc. Announces Date for 2025 Annual Stockholder Meeting

Reuters
·
Nov 01

BRIEF-BioXcel Therapeutics Inc - Updates On sNDA Submission For IGALMI Label Expansion - SEC Filing

Reuters
·
Oct 30

BioXcel Therapeutics Inc - Updates on Snda Submission for Igalmi Label Expansion - SEC Filing

THOMSON REUTERS
·
Oct 30

BioXcel Therapeutics Reports Positive Phase 3 Results for IGALMI At-Home Use

Reuters
·
Oct 30

H.C. Wainwright Keeps Their Buy Rating on Bioxcel Therapeutics (BTAI)

TIPRANKS
·
Oct 16

BioXcel Therapeutics Announces Positive Correlation Study Results Supporting At-Home Use of BXCL501 for Acute Agitation

Reuters
·
Oct 14

BioXcel Therapeutics Inc - No Serious Adverse Events Reported in Study

THOMSON REUTERS
·
Oct 14

BioXcel Therapeutics Inc - Results to Be Included in Snda Submission Planned for Q1 2026

THOMSON REUTERS
·
Oct 14

BioXcel Therapeutics Announces Positive Results From Correlation Study Supporting Serenity at-Home Exploratory Efficacy Outcomes

THOMSON REUTERS
·
Oct 14

BioXcel Therapeutics Completes Enrollment in Clinical Study to Evaluate mCGI-S and PEC Scale Correlation, Results Expected Q4 2025

Reuters
·
Sep 15

BioXcel Therapeutics Inc : Mizuho Raises Target Price to $4 From $2

THOMSON REUTERS
·
Sep 12

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bioxcel Therapeutics (BTAI) and Alignment Healthcare (ALHC)

TIPRANKS
·
Sep 11

BioXcel Therapeutics Announces Positive Results from Phase 3 SERENITY At-Home Trial for Agitation Treatment in Bipolar and Schizophrenia Patients

Reuters
·
Sep 10

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data From Serenity at-Home Pivotal Phase 3 Safety Trial for Agitation Associated With Bipolar Disorders or Schizophrenia

THOMSON REUTERS
·
Sep 10